Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1 reverse transcriptase inhibitors.

Yazan El Safadi1, Valérie Vivet-Boudou, Roland Marquet

  • 1Architecture et Réactivité de l'ARN, Université Louis Pasteur, CNRS, IBMC, 15 rue René Descartes, 67084, Strasbourg cedex, France.

Applied Microbiology and Biotechnology
|March 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-AUG HIV-1 uORF translation elicits specific T cell immune response and regulates viral transcript expression.

Nature communications·2025
Same author

MMTV RNA packaging requires an extended long-range interaction for productive Gag binding to packaging signals.

PLoS biology·2024
Same author

A specific domain within the 3' untranslated region of Usutu virus confers resistance to the exonuclease ISG20.

Nature communications·2024
Same author

Structural Impact of the Interaction of the Influenza A Virus Nucleoprotein with Genomic RNA Segments.

Viruses·2024
Same author

Identification of a putative Gag binding site critical for feline immunodeficiency virus genomic RNA packaging.

RNA (New York, N.Y.)·2023
Same author

Sequential disruption of SPLASH-identified vRNA-vRNA interactions challenges their role in influenza A virus genome packaging.

Nucleic acids research·2023
Same journal

Biocontrol of mushroom crop mycoparasites by novel Bacillus velezensis strains.

Applied microbiology and biotechnology·2026
Same journal

Removal and analysis of foodborne-associated pathogens via peptide functionalized nanoparticles.

Applied microbiology and biotechnology·2026
Same journal

Targeting thioredoxin reductase for anti-tuberculosis drug discovery: the inhibitor OSSL_632214.

Applied microbiology and biotechnology·2026
Same journal

Total fungal RNA extraction from complex solid- state fermentation products.

Applied microbiology and biotechnology·2026
Same journal

Role of Aspergillus neutral protease II in heat-induced soy sauce sediment formation.

Applied microbiology and biotechnology·2026
Same journal

Cysteine-S-conjugate β-lyase: a green catalyst for the production of flavor-active mercaptoketones.

Applied microbiology and biotechnology·2026
See all related articles

This study reviews human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitors, crucial for treating AIDS. It details their mechanisms, resistance, side effects, and future development for effective antiretroviral therapy.

Area of Science:

  • Virology
  • Pharmacology
  • Drug Development

Background:

  • Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is a key enzyme in AIDS pathogenesis.
  • RT inhibitors are essential components of highly active antiretroviral therapy (HAART), significantly improving outcomes for people with HIV-1/AIDS.
  • Current research focuses on FDA-approved and clinically trialed RT inhibitors.

Purpose of the Study:

  • To review the mechanisms of action for different classes of RT inhibitors.
  • To analyze viral resistance mechanisms against RT inhibitors.
  • To discuss the side effects and future perspectives for developing novel RT inhibitors.

Main Methods:

  • Review of US Food and Drug Administration (FDA)-approved RT inhibitors.

Related Experiment Videos

  • Analysis of RT inhibitors in clinical phases II and III trials.
  • Examination of drug mechanisms, resistance, and side effects.

    • Main Results:

    • RT inhibitors are categorized into two main classes: Nucleoside RT inhibitors (NRTIs) and Non-NRTIs.
    • NRTIs function as chain terminators by lacking a 3' hydroxyl group.
    • Non-NRTIs inhibit polymerization by binding to a hydrophobic pocket near the active site.

    Conclusions:

    • Understanding RT inhibitor mechanisms and resistance is vital for effective HIV-1/AIDS treatment.
    • Continued development of novel RT inhibitors is necessary to combat viral resistance and improve therapeutic options.
    • This review provides a comprehensive overview of current and future RT inhibitor strategies.